Ciclesonide市場：依適應症、劑型和地區分類

Ciclesonide Market, By Indication (Allergy Rhinitis and Asthma), By Dosage Form (Aerosol and Nasal Spray), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年06月01日 | 出版商:

Coherent Market Insights | 英文 255 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，Ciclesonide市場規模將達到 6.581 億美元，到 2033 年將達到 7.508 億美元。預計 2026 年至 2033 年的複合年成長率為 1.9%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	6.581億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	1.90%	2033年市場規模預測：	7.508億美元

Ciclesonide是一種吸入型糖皮質激素（ICS），建議用於緩解氣喘和慢性阻塞性肺病（COPD）患者的呼吸困難、胸悶、喘息和咳嗽等症狀。吸入藥物，包括吸入型糖皮質激素、長效BETA2腎上腺素受體促效劑（LABA）和長效毒蕈鹼受體拮抗劑（LAMA），是COPD治療的重要選擇。吸入型糖皮質激素通常被認為在成人和兒童中均安全且耐受性良好。Ciclesonide的安全性更高，且與其他藥物療效相當，提示其可能有助於提高氣喘和COPD患者的用藥依從性，並改善治療效果。

然而，一些研究對成人慢性阻塞性肺病（COPD）患者常規使用吸入性糖皮質激素（ICS）可能增加肺炎風險表示擔憂。發表於《呼吸病學雜誌》（Respirology Journal: 2013）的一項研究顯示，長期服用ICS的氣喘兒童發生肺炎鏈球菌口咽定植的風險增加。這可能導致預測期內患者使用Ciclesonide受到限制。

市場動態

過敏性鼻炎和氣喘的高發病率，以及主要地區頻繁的產品獲批和上市，預計將在預測期內推動市場成長。例如，根據2018年發布的《全球氣喘報告》，全球每天約有1,000人死於氣喘，估計全球有3.39億人患有氣喘。此外，2012年，食品藥物管理局生產的Zetona（Ciclesonide）鼻用氣霧劑獲得FDA批准，用於治療過敏性鼻炎，並在美國市場上市。

此外，大型企業策略性併購的增加預計將支持並推動市場成長。 2012年，武田藥品工業株式會社的子公司Nycomed在阿拉伯聯合大公國（阿拉伯聯合大公國）推出了用於治療12歲及以上成人和青少年過敏性鼻炎的Omnaris（Ciclesonide）鼻噴霧。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球環Ciclesonide市場主要參與者的概況：公司概況、財務表現、產品系列、企業發展區域、分銷策略、主要發展和策略以及未來計劃。
本報告提供的見解將有助於企業負責人和經營團隊就未來的產品升級、市場擴張和行銷策略做出明智的決策。
這份全球環Ciclesonide市場報告旨在為行業內的各類相關人員提供參考，包括投資者、研究機構、Ciclesonide生產商、經銷商、新參與企業和金融分析師。
相關人員可以利用Ciclesonide市場分析中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- AstraZeneca Plc
- Cipla Limited
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2291

Ciclesonide Market is estimated to be valued at USD 658.1 Mn in 2026 and is expected to reach USD 750.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 1.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 658.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	1.90%	2033 Value Projection:	USD 750.8 Mn

Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting B2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

However, some of the studies raised concerns regarding increased risk of pneumonia related to regular use of ICS in adult patients with chronic obstructive pulmonary disease. A study findings published in the Respirology Journal: 2013, revealed an increased risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma regularly taking ICS. This could potentially lead to restrict application of ciclesonide by patients during the forecast period.

Market Dynamics

Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2018, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.

Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

Key features of the study

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global ciclesonide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study includes AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics.
The global ciclesonide market report caters to various stakeholders in this industry including investors, researchers, ciclesonide manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the ciclesonide market.

Market Segmentation

By Indication (Revenue, USD Mn, 2021-2033)
Allergy Rhinitis
Asthma
By Dosage Form (Revenue, USD Mn, 2021-2033)
Aerosol
Nasal Spray
By Region (Revenue, USD Mn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
AstraZeneca Plc
Cipla Limited
Sun Pharmaceutical Industries Ltd.
Apotex Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Dosage Form
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Ciclesonide Market, By Indication, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Allergy Rhinitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Ciclesonide Market, By Dosage Form, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Ciclesonide Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- AstraZeneca Plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Cipla Limited
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Apotex Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views